AZD2171

Jump to: navigation, search
AZD2171
250px
Clinical data
Routes of
administration
Oral
Pharmacokinetic data
Elimination half-life12 to 35 hours
Identifiers
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC25H27FN4O3
Molar mass450.5 g/mol

WikiDoc Resources for AZD2171

Articles

Most recent articles on AZD2171

Most cited articles on AZD2171

Review articles on AZD2171

Articles on AZD2171 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on AZD2171

Images of AZD2171

Photos of AZD2171

Podcasts & MP3s on AZD2171

Videos on AZD2171

Evidence Based Medicine

Cochrane Collaboration on AZD2171

Bandolier on AZD2171

TRIP on AZD2171

Clinical Trials

Ongoing Trials on AZD2171 at Clinical Trials.gov

Trial results on AZD2171

Clinical Trials on AZD2171 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on AZD2171

NICE Guidance on AZD2171

NHS PRODIGY Guidance

FDA on AZD2171

CDC on AZD2171

Books

Books on AZD2171

News

AZD2171 in the news

Be alerted to news on AZD2171

News trends on AZD2171

Commentary

Blogs on AZD2171

Definitions

Definitions of AZD2171

Patient Resources / Community

Patient resources on AZD2171

Discussion groups on AZD2171

Patient Handouts on AZD2171

Directions to Hospitals Treating AZD2171

Risk calculators and risk factors for AZD2171

Healthcare Provider Resources

Symptoms of AZD2171

Causes & Risk Factors for AZD2171

Diagnostic studies for AZD2171

Treatment of AZD2171

Continuing Medical Education (CME)

CME Programs on AZD2171

International

AZD2171 en Espanol

AZD2171 en Francais

Business

AZD2171 in the Marketplace

Patents on AZD2171

Experimental / Informatics

List of terms related to AZD2171


Overview

AZD2171 (tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is being developed by AstraZeneca as a possible chemotherapeutic agent for oral administration.

As of 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumors of the central nervous system in children.

Further reading

  • Wedge S, Kendrew J, Hennequin L; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. PMID 15899831.

External links



Linked-in.jpg